Acrux (ASX:ACR) is set to bring its transdermal Estradiol spray Lenzetto® to the Australian market after expanding its licensing agreement with long-term partner Gedeon Richter Plc. The move could deliver Acrux up to AUD 5.4 million in milestone payments over a set period. The amended agreement comes at a critical time for Australian women, with
Read MorePharmaceutical companies are increasingly targeting drugs nearing patent expiry, using reformulation strategies to unlock value in large, established markets. By improving the delivery and usability of known compounds, companies can access significant global opportunities while leveraging existing safety profiles. EVE Health Group Limited (ASX:EVE) is advancing this approach, raising $0.9 million to support expansion across
Read More
Pharmaceutical and consumer health company, Bioxyne (ASX: BXN) has become the first manufacturer in Australia to produce cannabis gummies under a Good Manufacturing Practice (GMP) licence. Through its subsidiary, Breathe Life Sciences (BLS), Bioxyne has completed the first commercial run of these pharmaceutical-grade edibles, taking an early position in Australia’s fast-evolving medicinal cannabis market where
Read More
About 57 people are diagnosed with breast cancer every day in Australia, with instances having grown over the past decade. New and improved treatments are crucial, and to address that, Australian diagnostics company INOVIQ (ASX: IIQ) has developed a special exosome therapy that can target and kill breast cancer cells in lab tests. The Company
Read More
Pharmaceuticals company AusCann (ASX: AC8) is set to progress to the next stage of clinical trials having successfully completed their first round on Neuvis, their cannabinoid-based capsule developed to treat nerve pain – an area of medicine that is inadequately met. Estimated to affect 7-10% of Australians, nerve pain is caused by damage to the
Read More